Activation of toll-like receptor 3 protects against DSS-induced acute colitis

Matam Vijay-Kumar, Huixia Wu, Jesse Aitken, Vasantha L. Kolachala, Andrews Neish, Shanthi V. Sitaraman, Andrew T. Gewirtz

Research output: Contribution to journalArticlepeer-review

109 Scopus citations

Abstract

Background: Mimetics of bacterial DNA, given orally or subcutaneously, protect mice from experimental colitis via a toll-like receptor (TLR)-9-dependent mechanism. The goal of the study was to define whether synthetic viral RNA, polyinosinic acid:cytidylic acid [poly(I:C)], which is also a potent immunomodulator, might also affect murine colitis and, if so, define whether such effects were mediated by TLR3, which is one of at least 4 known receptors for this viral RNA analog. Methods: Mice (C57BL6, IL-10KO, or TLR3 KO) were administered 1.5% dextran sodium sulfate (DSS) in drinking water for 7 days. Two hours before treatment with DSS, mice were given phosphate-buffered saline (PBS) or poly(I:C) 20 μg subcutaneously (s.c), or 100 μg intragastrically (i.g.). Results: In wildtype mice s.c. administration of poly(I:C) dramatically protected against DSS-induced colitis as assessed by every parameter analyzed, which included body weight, rectal bleeding, colonic myeloperoxidase, histopathology, serum keratinocyte-derived chemokine, serum amyloid A, and lipocalin-2. In contrast, i.g. administration of poly(I:C) offered no protection in this colitis model nor did its administration activate the innate immune system as assessed by serologic parameters. Subcutaneous poly(I:C) protected against DSS-induced colitis equally well in C57BL6 and IL-10KO mice, indicating that this antiinflammatory cytokine is not required for such protection. Protection against colitis given by poly(I:C) treatment was ablated in TLR3 KO, indicating that the protective action of this viral RNA analog was mediated by this receptor. Conclusions: Activation of TLR3 on cells that are accessible by systemic, but not oral, administration of synthetic viral RNA results in protection against the acute inflammation that can ensue upon damage of the gut epithelium. Thus, this viral RNA analog, which is under clinical trials for other inflammatory disorders (e.g., lupus), may also have therapeutic value for inflammatory bowel disease.

Original languageEnglish (US)
Pages (from-to)856-864
Number of pages9
JournalInflammatory bowel diseases
Volume13
Issue number7
DOIs
StatePublished - Jul 2007

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Fingerprint Dive into the research topics of 'Activation of toll-like receptor 3 protects against DSS-induced acute colitis'. Together they form a unique fingerprint.

Cite this